Related Experiment Video
Updated: May 6, 2026
Activated Cross-linked Agarose for the Rapid Development of Affinity Chromatography Resins - Antibody Capture as a Case Study
Published on: August 16, 2019
Expression and purification of a human anti-cyclin D1 single-chain variable fragment antibody AD5 and its
Yan Wu1, Desheng Zou, Yuhua Cao
1Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, College of Life Science, Jilin University, Changchun, Jilin 130012, P.R. China.
Abstract:
Cyclin D1 plays an important role in cell cycle progression. Increasing evidence indicates that cyclin D1 is overexpressed in the majority of tumor cells and has become a potential target for tumor therapy. However, little research has been done on the specific inhibition of cyclin D1 for cancer therapy. With the rapid development of the phage display antibody library technique, single-chain variable fragment (scFv) antibodies have emerged, which have tremendous application prospects in cancer therapy and diagonosis. In this study, a human scFv binding specifically to cyclin D1 (AD5) that was derived from a human semi-synthetic scFv phage library was expressed in the soluble form in Escherichia coli (E. coli) HB2151 cells. To characterize AD5, soluble AD5 was purified successfully through ammonium sulfate precipitation and affinity chromatography from the culture supernatant of AD5/HB2151. ELISA assay revealed that purified soluble AD5 could specifically bind to human recombinant cyclin D1 with approximately (1.19±0.056) x 107 M-1 affinity constant and showed approximately 52% competitive inhibition with the anti-cyclin D1 polyclonal antibody for binding to cyclin D1 in vitro. These results suggest that the scFv antibody against cyclin D1 may be a novel potential tool for targeting cyclin D1 in cancer therapy and diagnosis.
Insights
Researchers developed a novel single-chain variable fragment (scFv) antibody, AD5, that specifically targets cyclin D1. This antibody shows potential as a tool for cancer therapy and diagnosis by inhibiting cyclin D1 activity.
Area of Science:
- Molecular Biology
- Immunology
- Oncology
Background:
- Cyclin D1 is crucial for cell cycle progression and frequently overexpressed in tumors.
- Targeting cyclin D1 is a promising strategy for cancer therapy, but specific inhibitors are underexplored.
- Single-chain variable fragment (scFv) antibodies offer potential for cancer diagnosis and treatment.
Purpose of the Study:
- To develop and characterize a human scFv antibody (AD5) that specifically binds to cyclin D1.
- To evaluate the potential of AD5 as a therapeutic and diagnostic tool for cyclin D1-related cancers.
Main Methods:
- A human semi-synthetic scFv phage display library was used to isolate AD5.
- AD5 was expressed in soluble form in Escherichia coli (E. coli) HB2151 cells.
- Purification involved ammonium sulfate precipitation and affinity chromatography; binding affinity and inhibition were assessed via ELISA.
Main Results:
- Soluble AD5 was successfully purified from E. coli culture supernatant.
- ELISA confirmed specific binding of AD5 to human recombinant cyclin D1 with an affinity constant of approximately 1.19 x 10^7 M^-1.
- AD5 demonstrated approximately 52% competitive inhibition against anti-cyclin D1 polyclonal antibodies in vitro.
Conclusions:
- The developed scFv antibody, AD5, specifically targets cyclin D1.
- AD5 exhibits significant binding affinity and inhibitory capacity against cyclin D1.
- These findings suggest AD5 is a potential novel tool for targeting cyclin D1 in cancer therapy and diagnosis.
